World's Safety In Hands Of A Few Biotechs; Who Cares?
This article was originally published in Scrip
Executive Summary
The safety of the US, and even the rest of the world, against biological threats – either manmade or natural – rests in the hands of a relatively small number of biopharmaceutical companies, most of which are small private firms, whose investors are reluctant to stick around if there's an unclear regulatory pathway and an uncertain market for the products those firms produce, Jim Greenwood, president and CEO of the Biotechnology Innovation Organization, told a House subcommittee on Feb. 12.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.